Bullish Case: CBT’s $83.87 price is near Helium’s and market-implied probability peaks around $85, while the historical-return surface concentrates on modest moves rather than persistent losses. Flat CBT term structure and roughly 26–33% near-the-money IV leave room for a catalyst repricing. Liquidity extension through 2031 and the Zacks upgrade support the earnings narrative, though realization depends on margin stabilization and upcoming results.

Bearish Case: CBT remains 10.2% below its 60-day price, trades at 5.0× book, and puts recently exceeded calls by 9%. Deep downside IV is extreme—roughly 65–118% in quoted but largely inactive strikes—signaling fragile tail pricing rather than reliable probabilities. The SPY surface also shows materially richer downside volatility over longer horizons. Reinforcement-material pricing pressure or weak guidance could invalidate the bullish narrative quickly.

Potential Outcomes:

1. 52% — Range/mean reversion: $79.70–$88.10; consistent with the return surface and prior sideways call, which was directionally validated.
2. 20% — Catalyst grind to $89–94 by Jan. 15 if margins improve.
3. 18% — Drift to $74–79 on weak guidance or SPY risk-off.
4. 7% — ≤$71 shock; falsified by deep-put IV falling and quotes tightening.
5. 3% — Execution-driven mispricing. Oracle: reassess after Aug. 28 and Sep. 18; call IV rising without put-IV expansion is bullish confirmation.

August 25, 2026